Cosmo Announces Completion of Phase II Enrolment in Distal Ulcerative Colitis Program @Cosmo_Pharma #HealthCare #OTC #OTCMarkets #OTCStocks #Investing
Dublin, Ireland--(Newsfile Corp. - May 18, 2026) - Cosmo N.V. (SIX: COPN) (XETRA: C43) (“Cosmo” or “the Company”) today announced the completion of patient enrolment in its Phase II clinical trial (EUCT number: 2023-506917-23-00) evaluating its novel investigational therapy, Rifamycin enema, for the treatment of distal ulcerative colitis (UC) and ulcerative proctitis. A total of 77 patients were enrolled at 24 clinical sites in Europe, reflecting strong investigator engagement...
http://dlvr.it/TSbDxZ
http://dlvr.it/TSbDxZ
Comments
Post a Comment